Advances in the treatment of hepatitis C and various types of cancer could have a dramatic impact on the specialty market as soon as this year, according to Aimee Tharaldson, PharmD, an Express Scripts senior clinical consultant who analyzes the specialty pharmaceutical pipeline. Hep C treatments from Gilead, Abbvie, Enanta, Merck, and BMS could dramatically reduce the prevalence of hepatitis C, albeit at a very high price. There are also important new cancer drugs that could soon enter the market, with 30% of specialty drugs currently in the pipeline being developed to treat various forms of the disease. Read more. (Source: Specialty Pharmacy Times, 4/9/2014)
You are here: / / What treatments are looming in the specialty pipeline?